Financial Analysis: BioRestorative Therapies (OTCMKTS:BRTX) and CNBX Pharmaceuticals (OTCMKTS:CNBX)

Profitability

This table compares CNBX Pharmaceuticals and BioRestorative Therapies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CNBX Pharmaceuticals	N/A	N/A	N/A
BioRestorative Therapies	-13,728.83%	-120.47%	-114.48%

Insider & Institutional Ownership

98.2% of CNBX Pharmaceuticals shares are held by institutional investors. Comparatively, 69.4% of BioRestorative Therapies shares are held by institutional investors. 73.5% of CNBX Pharmaceuticals shares are held by company insiders. Comparatively, 30.8% of BioRestorative Therapies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares CNBX Pharmaceuticals and BioRestorative Therapies”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CNBX Pharmaceuticals	N/A	N/A	N/A	($0.01)	-0.04
BioRestorative Therapies	$383,400.00	24.08	-$18.50 million	($1.47)	-0.71

CNBX Pharmaceuticals has higher earnings, but lower revenue than BioRestorative Therapies. BioRestorative Therapies is trading at a lower price-to-earnings ratio than CNBX Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

CNBX Pharmaceuticals beats BioRestorative Therapies on 7 of the 8 factors compared between the two stocks.

About CNBX Pharmaceuticals

CNBX Pharmaceuticals Inc., a clinical stage company, engages in the discovery, development, and commercialization of novel cannabinoid-based products and technologies for the treatment of cancer. Its lead product candidate is Cannabics SR, an oral capsule developed for the treatment of patients with advanced cancer and cancer anorexia cachexia syndrome. The company is also developing various drug candidates, including PLP-33 for the treatment of lateral spreading or sessile, and colorectal polyps during colonoscopy; BRST-33 to treat breast cancer; MLN-33 for the treatment of Melanoma; and PRST-33 to treat prostate cancer. In addition, it is developing RCC-33, an oral capsule containing a formulation of cannabinoids for the treatment of colorectal cancer; and Cannabics CDx, an ex-vivo drug sensitivity test. The company was formerly known as Cannabics Pharmaceuticals Inc. and changed its name to CNBX Pharmaceuticals Inc. in March 2022. CNBX Pharmaceuticals Inc. was incorporated in 2004 and is based in Bethesda, Maryland. The company is a subsidiary of Cannabics Inc.

About BioRestorative Therapies

BioRestorative Therapies, Inc. engages in the development of therapeutic products and medical therapies using cell and tissue protocols. Its programs provide quality of care for chronic back pain caused by disc degeneration and metabolic disorders, including obesity and diabetes. The company’s initial investigational therapeutic product being called BRTX-100 focuses on treating damage by an autologous stem cell product that uses own stem cells that are harvested, cultured, and then injected directly into the affected disc to start the repair process. BioRestorative Therapies was founded on June 13, 1997 and is headquartered in Melville, NY.